Geri

HORMON THERAPY IN THE MANAGAMENT OF POSTMENOPAUSAL OSTEOPOROSIS: CURRENT ASPECTS

Makale

Cilt 9, Sayı 3

Mayıs 2006 · Sayfalar 192-194

HORMON THERAPY IN THE MANAGAMENT OF POSTMENOPAUSAL OSTEOPOROSIS: CURRENT ASPECTS

Aygül DEMİROL1, Süleyman GÜVEN2, E. Seda GÜVENDAĞ GÜVEN3, Timur GÜRGAN3

1Clinic Kadın Sağlığı İnfertilite ve Tüp Bebek Merkezi, ANKARA
2Kadın Hastalıkları ve Doğum Uzmanı Serbest Hekim, ANKARA
3Hacettepe Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, ANKARA
Anahtar Kelimeler: Postmenopausal osteoporosis Management Hormon therapy Estrogen

Osteoporosis is a common condition in postmenopausal women and is associated with morbidity and mortality. It is clear that long-term hormone therapy (HT) has a role to play in preventing osteoporosis by increasing bone mineral density and reducing fracture rate. Although hormone therapy has demonstrated clinical fracture risk reduction; safety outcomes from the Women's Health Initiative (WHI) study have raised concerns regarding long-term use of HT. However WHI suggesting that the incidence of breast cancer, coronary heart disease, stroke, and venous thromboembolism increases following long-term use of HT. In conlusion, estrogen is an option for the prevention of osteoporosis in perimenopausal women, but we no longer consider it a first-line therapy.